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Purpose: Intensity modulated proton therapy (IMPT) plans are normally generated utilizing multiple field optimization
(MFO) techniques. Similar to photon based IMRT, MFO allows for the utilization of a simultaneous integrated boost in
which multiple target volumes are treated to discrete doses simultaneously, potentially improving plan quality and
streamlining quality assurance and treatment delivery. However, MFO may render plans more sensitive to the physical
uncertainties inherent to particle therapy. Here we present clinical examples of a single-field integrated boost (SFIB)
technique for spot scanning proton therapy based on single field optimization (SFO) treatment-planning techniques.
Methods and materials: We designed plans of each type for illustrative patients with central nervous system (brain and
spine), prostate and head and neck malignancies. SFIB and IMPT plans were constructed to deliver multiple prescription
dose levels to multiple targets using SFO or MFO, respectively. Dose and fractionation schemes were based on the
current clinical practice using X-ray IMRT in our clinic. For inverse planning, dose constraints were employed to achieve
the desired target coverage and normal tissue sparing. Conformality and inhomogeneity indices were calculated to
quantify plan quality. We also compared the worst-case robustness of the SFIB, sequential boost SFUD, and IMPT plans.
Results: The SFIB technique produced more conformal dose distributions than plans generated by sequential boost
using a SFUD technique (conformality index for prescription isodose levels; 0.585 ± 0.30 vs. 0.435 ± 0.24, SFIB vs. SFUD
respectively, Wilcoxon matched-pair signed rank test, p < 0.01). There was no difference in the conformality index
between SFIB and IMPT plans (0.638 ± 0.27 vs. 0.633 ± 0.26, SFIB vs. IMPT, respectively). Heterogeneity between techniques
was not significantly different. With respect to clinical metrics, SFIB plans proved more robust than the corresponding
IMPT plans.
Conclusions: SFIB technique for scanning beam proton therapy (SSPT) is now routinely employed in our clinic. The SFIB
technique is a natural application of SFO and offers several advantages over SFUD, including more conformal plans,
seamless treatment delivery and more efficient planning and QA. SFIB may be more robust than IMPT and has been the
treatment planning technique of choice for some patients.
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In spot scanning proton therapy (SSPT), a pencil beam
(spot) is magnetically scanned in both directions lateral
to the beam direction to produce a large field without the
introduction of scattering elements or range modulation
devices into the beam path [1-4]. Monoenergetic pencil
beams of different energies are used to produce the
desired depth dose distribution. The intensity of each spot
can also be modulated to deliver intensity-modulated
proton therapy (IMPT) [5-9]. To achieve the desired dose
distribution over the target volumes, the weights of
individual spots are optimized using an inverse plan-
ning process. There are two general approaches to
optimizing a SSPT plan. The first is to optimize the
weights of all spots in all fields simultaneously to
produce the desired dose distribution. This approach
is called multiple-field optimization (MFO), and is
more commonly known as IMPT [5-10]. The second
approach is to optimize the weights on a field-by-field
basis, that is, each field is optimized individually to
deliver a fraction of the prescribed doses to the entire
target volume(s). This method is called single-field
optimization (SFO) [11]. The most common application
of SFO is to produce a uniform dose over the entire target
volume by each field, known as single–field uniform dose
(SFUD) [5,11-13].
An extension of SFO techniques would allow for the
incorporation of a simultaneous integrated boost (SIB), an
approach which we have termed, single field integrated
boost (SFIB). The concept of SIB was originally proposed
for intensity modulated radiation therapy (IMRT) using
photons [14] and has been widely used since. For a patient
with multiple target volumes to be treated at different
prescription dose levels, one could develop multiple
treatment plans using SFUD to sequentially treat the
patient. However, optimizing plans separately may produce
inferior results when plans are combined. Moreover,
additional time is required for treatment planning as
well as quality assurance of individual plans. Like
IMRT, IMPT can be naturally used to achieve SIB
[5-9]. IMPT is considered more flexible than SFUD and
often delivers more conformal dose distribution to target
volumes and lower doses to critical structures. However,
IMPT plans may be more sensitive to the uncertainties
associated with proton therapy and thus less robust
than SFUD plans [7]. Given the limitations of current
commercial treatment planning systems (TPS), at the
University of Texas MD Anderson Cancer Center
(UTMDACC) Proton Therapy Center, we normally treat
our patients with the SFO (either SFUD or SFIB)
technique [13], unless the IMPT plan is significantly
better than the SFO plan. In this work, we present
examples of treatment planning techniques of SFIB
implemented in our clinic.Materials and methods
Patients and treatment planning
Since April 2010, we have employed an SFIB technique
for planning and treatment of patients at the UTMDACC
proton therapy center. Diseases planned and treated with
this technique include prostate cancer, thoracic tumors,
central nervous system tumors (brain and spinal lesions),
and head and neck tumors. All patients are enrolled in
Institutional Review Board approved prospective studies
of proton therapy. To demonstrate the SFIB technique
and qualitatively assess it’s benefits and versatility, here we
present four representative clinical cases each with
multiple target volumes requiring different dose levels.
We utilized SFO planning with dose constraints employed
to achieve the desired coverage of different target volumes
by differing dose levels within in a single plan. Target vol-
umes treated with the SFIB technique may include a target
within a target, such as for patient 1 and 4; targets located
side by side, such as for patient 3; or a combination of these
two situations, such as for patient 2 (see below for detailed
description of each case).
SFIB treatment plans as well as sequential boost SFUD
and IMPT plans were generated for comparison. Dose
levels for SFUD plans were determined based on the
linear quadratic model and the dose levels chosen by the
treating physician for the clinically utilized SFIB plan.
Doses were rounded to integer number of fractions.
IMPT plans used identical dose levels as SFIB plans.
Treatment plans for all patients were developed using
computed tomography (CT) images obtained using
120-kV X-rays on a 16-slice scanner (LightSpeed RT 16;
GE Healthcare, Waukesha, WI). In treatment planning, all
proton doses were expressed as Gy(RBE) with a constant
RBE factor of 1.1. The Eclipse TPS (version 8.9; Varian
Medical Systems, Palo Alto, CA) with a proton module
was used. Inverse planning using an SFO and MFO
options with simultaneous spot optimization, using
constraints for target volumes and critical structures,
was used for all patients. The details of our clinical
commissioning of the scanning beam dose model in TPS is
described separately [15]. Each spot’s position, energy, and
number of monitor units (MUs) were determined using
the TPS. Beam parameters for each field are summarized
in Table 1.
Patient 1 central nervous system - brain
A young patient with a glioma of the tectal plate was
treated with SSPT. The patient was immobilized using a
Precise Bite positioner attached to a thermoplastic mask
with a polyurethane foam headrest (CIVCO Medical
Solutions, Orange City, IA). The SFUD, SFIB and IMPT
plans used the same three fields: two left oblique superior
vertex fields and one posterior– anterior (PA) field.
For SFIB and IMPT planning, the clinically prescribed
Table 1 Field parameters










1 Left vertex 1 60°/290° 138.1/91.1 13.3/6.2 0.80/1.16 30 1.2
Posterior 180°/0° 144.9/106.6 14.5/8.3 0.77/1.02 22 1.2
Left vertex 2 95°/290° 134.6/91.9 12.7/6.3 0.82/1.16 29 1.2
2 Posterior 180°/0° 132.8/79.7 12.4/4.8 0.83/1.33 37 1.1
3 Right lateral 270°/0° 198.3/155.3 25.2/16.4 0.59/0.73 19 0.64
Left Lateral 90°/0° 198.3/155.3 25.2/16.4 0.59/0.73 19 0.64
4 Right anterior 300°/15° 143.2/96.9 7.5/0.3* 0.95/1.59 32 1.0
Right lateral 270°/15° 139.8/96.9 6.9/0.3* 0.97/1.59 30 1.0
Abbreviations: Max maximum, Min minimum, E energy, R range, σair sigma of spot in air at the isocenter. Spot spacing, center-to-center distance of spot. *With a
range shifter of 6.7 g/cm2.
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CTV2, respectively, in 30 fractions. The corresponding
dose to CTV2 for the SFUD plan was 45 Gy(RBE) in 25
fractions, followed by a boost to 54 Gy(RBE) for CTV1.
The planning target volume (PTV) was defined as a
3-mm expansion of the CTV. Strictly speaking, the
PTV concept commonly used in photon therapy cannot
be directly used for proton therapy because the range
uncertainties are beam-direction-specific. However, beam-
specific PTVs (bsPTVs) [16] are not available in our
clinical TPS. We nevertheless currently use the PTV
concept in spot scanning proton therapy to manage
delivery uncertainties for plans with a non-parallel-opposed
beam arrangements [7].
Patient 2 central nervous system - spine
An adult patient with a myxopapillary ependymoma of
the spine was treated with SSPT with a single PA field.
The patient was immobilized in the supine position with
a knee and foot-positioning device (CIVCO Medical
Solutions, Orange City, IA). A digital model of the treat-
ment couch with correct water-equivalent thickness was
used to replace the CT couch. For SFIB planning and
treatment, the prescription doses were 54, 50.4 and 45 Gy
(RBE) to the CTV1, CTV2, and CTV3, respectively, in 28
fractions. The corresponding doses for the SFUD plan
were calculated at 50.2 Gy(RBE) to CTV2 in 26 fractions
and 42.5 Gy(RBE) for CTV3 in 22 fractions. The PTVs
were defined as a 3-mm expansion of the CTVs except
the anterior expansion of 5 mm to account for range
uncertainty, but sparing the majority of the vertebral
bodies.
Patient 3 prostate
A gentleman with an adenocarcinoma of the prostate was
treated with SSPT with two equally weighted, parallel,
opposed lateral fields. The simulation and treatment
planning technique for prostate patients has been described
in detail previously [11,13,17]. PTVs defined for prostatepatients may be considered as a simplified version of
bsPTV [16] and used to account for range and setup
uncertainties. For SFIB and IMPT planning, the desired
prescription doses were 78 and 60 Gy(RBE) to the CTV1
and CTV2, respectively, in 39 fractions. The correspond-
ing dose to CTV2 for the SFUD plan was 54 Gy(RBE)
in 27 fractions, again followed by a boost to 78 Gy(RBE)
to CTV1.
Patient 4 head and neck
A patient with an acinic cell carcinoma of the right
parotid was treated with SSPT. The patient was immobilized
using a Precise Bite positioner attached to a thermoplastic
mask with a customized head mold using RediFoamTM
(RediFoam, CIVCO Medical Solutions, Orange City, IA).
The SFUD, SFIB and IMPT plans used the same two fields:
two left anterior oblique superior-inferior fields. For SFIB
and IMPT planning, the prescription doses were 64, 60 and
54 Gy(RBE) to the CTV1, CTV 2 and CTV3 in 30 fractions.
The corresponding dose to CTV2 and CTV3 for the SFUD
plan was 59.7 Gy(RBE) in 28 fractions and 51.2 Gy(RBE) in
24 fractions. The planning target volumes (PTVs) was also
defined as 3 mm expansion of the CTVs.
Conformality and inhomogeneity indices
Isodose distributions were compared visually on axial,
sagittal, and coronal slices to assess conformality to the
targets and sparing of normal tissues. Target coverage
and normal tissue sparing were also compared by dose
volume histograms (DVHs). In addition, target coverage
was quantitatively assessed by calculation of the conform-




index INH¼ D5−D95Dpre ; where PTV is the planning target
volume, PTVpre is the PTV covered by the prescription
dose, and Vpre is the volume of prescription isodose, D5
and D95 are the doses to 5% and 95% of the PTV as
displayed on the cumulative DVH, respectively, Dpre is the
















Figure 1 Representative isodose distributions on axial CT images for patient 1. (A) SFIB, (B) SFUD sequential boost and (C) IMPT treatment
plans for a central glioma. Targets and normal tissues are represented as color washes. (D) Dose volume histogram for corresponding plans. Solid
lines correspond to SFIB, dashed lines to SFUD, and dotted lines to IMPT. Exposure of right and left hippocampi to low and high doses is
reduced for SFIB and IMPT plans. (E) Comparison of measured (data points) and calculated (blue lines) depth dose curves for each of three
beams employed in the treatment of patient 1. Error bars are fixed values of 3% in the vertical axis and 2 mm in the horizontal axis to help
visualizing the difference between measurements and calculations.
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more inhomogeneous dose distribution.
Comparison of robustness
Robustness of the SFUD, SFIB and IMPT plans with
respect to setup and range uncertainties was evaluated
using a worst-case analysis method [19]. A setup
uncertainty of 3 mm was used for patients 1, 2 and 4
and 5 mm for patient 3. The range uncertainty was
assumed to be 3.5% of the nominal ranges [20]. Introducedperturbations included six spatial shifts along the three
major axes (left-right, posterior-anterior, and superior-
inferior) and two range shifts – for a total of 8 perturbed
dose distributions. The highest and lowest dose values in
each pixel were extracted from the nominal and the 8
perturbed dose distributions, forming a hot and cold
dose distributions with the highest and lowest values,
respectively [19]. The width of a banded DVH could
then be used to qualitatively represent the robustness of
the plans for a specific structure. We selected appropriate
Figure 2 Representative isodose distributions on sagittal CT images for patient 2. (A) SFIB and (B) SFUD treatment plans for a spinal ependymoma.
Targets and normal tissues are represented as color washes. (C) Dose volume histogram for corresponding plans (solid lines, SFIB; dashed lines, SFUD).
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and cold plans to compare the robustness of SFUD,
SFIB and IMPT plans. For target volumes, D95 and
D98 for CTVs and generalized equivalent uniform
dose (EUD = (ΣviDi
a)1/a, where vi is the fractional organ
volume receiving a dose Di and a is a tissue-specific
parameter that describes the volume effect) [14,21],
from the cold plans were used to compare the worst
case target coverage. The clinical criteria established
in our clinic, are, in the worst case (the cold plan),
D95 ≥ 95%, D98 ≥ 90% and EUD ≥100% of the prescription
dose. For normal tissues, the maximum dose (Dmax), meandose (Dmean) or the percent volume, VD, receiving certain
dose, D, or more and EUD from hot plans were used to
compare the worst case sparing. The EUD parameter a was
collected from literature [14,21]: for CTVs, a= -10; for spinal
cord, a= 20; for brainstem, hippocampus, optic chiasm,
cochlea, a= 16; for femoral heads, a= 12; for mandible, a=
10; for bladder, rectum a= 8; for larynx, a= 7.4; for kidney,
a= 5; and for submandibular gland and whole brain, a= 1.
Statistical analysis
The COIN, INH, target coverage in terms of D95, D98














Figure 3 Representative axial isodose distributions for treatment of a prostatic adenocarcinoma. Targets and normal tissues are represented
as color washes. Slices depicting treatment of CTV2 (seminal vesicles) as well as CTV1 (prostate) are shown in left and right panels for SFIB (A), SFUD
with sequential boost (B) and IMPT (C) plans. The dose volume histogram is shown in (D) (solid lines, SFIB; dashed lines, SFUD and dotted lines, IMPT).
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were compared statistically by the Wilcoxon matched-pairs
signed rank test using GraphPad Prim 6 software
(GraphPad Software, Inc., La Jolla, CA). A derived value
of p < 0.05 was considered statistically significant.
Results
Figure 1A-D depicts the isodose distributions and DVHs
between the SFIB, SFUD and IMPT plans for the glioma
patient. The SFIB planning technique produced a more
conformal dose distribution than the SFUD. Moreover,the SFIB technique achieved the desired dose coverage
for the target volumes and lower doses to critical normal
structures including the right and left hippocampus, and
whole brain. The IMPT plan had similar target coverage
as SFIB plan, however in this case, normal tissues had
similar or less dose. Panel E illustrates the calculated
and measured depth doses of the SFIB plan. Note that
the depth dose curves are not flat as would be a typical
curve from a passive scattering or SFUD plan. Instead,
we observe a rather non-uniform dose profile, as required
















Figure 4 Representative axial, coronal and sagittal (left, middle, and right panels, respectively) CT images for a patient 4. (A) SFIB,
(B) SFUD with sequential boost and (C) IMPT treatment plans. Targets volumes are represented as color washes. (D) Dose volume histogram
(solid lines, SFIB; dashed lines, SFUD and dotted line, IMPT).
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canal, a comparison of isodose distributions and DVHs
planned with the SFIB and SFUD technique are shown
in Figure 2, respectively and demonstrate that the SFIB
plan is qualitatively, more conformal than SFUD plan. Be-
cause this patient was treated with a single PA beam,
IMPT planning was not applicable.Figure 3 depicts a comparison of the isodose distributions
and DVHs between the SFIB, SFUD and IMPT plans for
the patient with adenocarcinoma of the prostate. SFIB
planning provided a slightly more conformal plan in
the region of CTV2 than SFUD. The SFIB technique
achieved the desired dose coverage for the target volumes
and similar doses to normal structures, including the
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similar target coverage as SFIB plan and a reduced rectum
dose but slightly increased femoral head dose.
Figure 4 is a comparison of the isodose distributions
and DVHs between the SFIB, SFUD and IMPT plans for
the head and neck patient. The SFIB technique achieved
a conformal dose distribution and met the desired dose
coverage for the target volumes while lowering doses
to some normal structures, such as the mandible and
larynx. The IMPT plans had similar coverage for the
target but lower doses to normal tissues.
Conformality index and inhomogeneity indices
Table 2 lists the COIN and INH values for PTV1 for
SFUD, SFIB and IMPT plans. For all four patients,
SFIB plans had larger COIN values than SFUD plans
(0.585 ± 0.300 vs. 0.435 ± 0.239, Wilconxon test, p < 0.01)
and thus were more conformal than SFUD plans. However,
the difference in COIN between SFIB and IMPT was not
significant. The inhomogeneity between all three planning
techniques was similar (Wilcoxon test, p = 0.81).
Robustness evaluation
Shown in Figure 5 is a summary of the comparison
of worst case robustness of SFUD, SFIB and IMPT
plans in terms of both target coverage and normal
tissue sparing in column bar plots. For target coverage
of all 4 patients, D95, D98 and EUD for the SFIB

















Mean ± SD (All patients) 0.435 ± 0.239* 0.585 ± 0.300*
Mean ± SD (exclude patient 2) 0.469 ± 0.232 0.638 ± 0.274
Abbreviations: COIN conformal index, INH inhomogeneity index, PTV planning target
IMPT intensity modulated proton therapy, SD standard deviation. *p < 0.01, Wilcoxocase, cold plans, Table 3 (mean ± standard deviation,
D95 = 100.0 ± 1.3 vs. 102.7 ± 5.0, D98 = 98.1 ± 2.1 vs.
101.1 ± 5.2, EUD = 104.6 ± 2.8 vs. 108.0 ± 6.1, SFIB vs.
SFUD, respectively, Wilcoxon test, p < 0.05 for D95,
D98, and EUD). This is consistent with SFIB plan being
more conformal than SFUD plans. Despite the slightly
smaller values of D95, D98 and EUD, all SFIB plans meet
the clinical criteria established in our clinic, that is, in the
worst case (the cold plan), D95 ≥ 95%, D98 ≥ 90% and
EUD ≥100% of the prescription dose (Table 3).
For target coverage of the three cases with IMPT
plans, D95, D98 and EUD for the IMPT plans were
smaller than SFIB plans in the worst case, cold plans,
Table 3 (mean ± standard deviation, D95 = 97.4 ± 3.3 vs.
101.1 ± 1.5, D98 = 93.6 ± 6.1 vs. 97.9 ± 2.4, EUD= 102.3 ± 4.1
vs. 105.5 ± 3.0, IMPT vs. SFIB, respectively, Wilcoxon test,
p < 0.05 for D95 and EUD, and p = 0.078 for D98). However,
some IMPT plans failed to meet the clinical criteria in the
worst case scenario (the cold plans), with minimum values
of D95, D98 and EUD of 92.7%, 82.4% and 95.4% of the
prescription doses respectively, values below our clinical
criteria (Table 3).
For normal tissues, SFIB was significant better than
SFUD even in the worst case (the hot plans) (dosimetric
parameters and EUDs in Figure 5, SFIB vs. SFUD,
Wilcoxon test, p < 0.01). One noted exception was the
mandible for patient 4 as presented in Figure 5H.
This exception is likely due to the fact that the mandible
overlapped with target volume in this case. On the othermogeneity
INH
IMPT SFUD SFIB IMPT
0.827 0.021 0.063 0.058
0.893 - -
- 0.066 0.056 -
- - - -
- - - -
0.851 0.043 0.038 0.057
0.154 - -
0.453 0.062 0.089 0.091
0.638 - -
0.613 - -
- 0.048 ± 0.021 0.062 ± 0.021 -
0.633 ± 0.263 0.042 ± 0.021 0.063 ± 0.026 0.069 ± 0.019
volume, SFIB single-field integrated boost, SFUD single field uniform dose,
n matched-pairs signed rank test.
Figure 5 Worst case robustness comparison of SFUD, SFIB and IMPT/MFO plans. The left column (blue) represents SFUD, the middle (red),
SFIB, and the right (green), IMPT plans. For target volumes, the cold plans are used to evaluate target coverage in terms of percentage of doses
of D95, D98 and EUD relative to the prescription doses. For critical structures, the hot plans are used assess the tissue sparing. (A) and (B) for
patient 1 (BS – brain stem, HC – hippocampus, OC – optical chiasm, PH – pituitary and hypothalamus, WB – whole brain); (C) and (D) for patient
2 (SC – spinal cord, LK – left kidney, RK – right kidney); (E) and (F) for patient 3 (BLD – bladder, RET – rectum, FH – femoral heads); and (G) and
(H) for patient 4 (LNX- larynx, RS – right submandibular, RC – right cochlea, and MDB – mandible).
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of normal tissues in the worst cases (hot plans) was
insignificant (Wilcoxon test, p = 0.58 and 0.45 for dosi-
metric parameters and EUDs, respectively).
Discussion
SSPT employing an SFIB approach is commonly used
in our clinical practice. Here, we have presented examplesof treatment plans utilizing the SFIB technique. We found
in each disease site, the SFIB technique generated more
conformal dose distributions than the SFUD technique.
Moreover, SFIB plans were robust in the face of uncertain-
ties. For target coverage, all SFIB plans meet clinical
criteria even in the worst-case scenario; for normal
tissues, the SFIB plans were most often superior to
SFUD plans with the exception cases where normal tissues
Table 3 Summary of the worst-case target coverage as percentage of prescription dose
SFUD% (range) SFIB% (range) IMPT% (range)
D95/Dpre (All patients) 102.7 ± 5.0 100 ± 1.3 -
(97.6-115.9) (97.6-102.5) -
D98/Dpre (All patients) 101.1 ± 5.2 98.1 ± 2.1 -
(95.2-114.2) (95.0-101.2) -
EUD/Dpre (All patients) 108.0 ± 6.1 104.6 ± 2.8 -
(101.6-120.2) (101.9-108.9) -
D95/Dpre (exclude patient 2) 103.8 ± 5.5 100.1 ± 1.5 97.4 ± 3.3
(99.7-115.9) (97.6-102.5) (92.7-101.9)
D98/Dpre (exclude patient 2) 101.9 ± 5.9 97.9 ± 2.4 93.6 ± 6.1
(95.2-114.2) (95.0-101.2) (82.4-100.4)
EUD/Dpre (exclude patient 2) 109.5 ± 6.7 105.5 ± 3.0 102.3 ± 4.1
(101.6-120.2) (101.9-108.9) (95.4-106.8)
Abbreviations: D95 and D98, doses to 95% and 98% of the target volumes as displayed on the cumulative DVH, respectively, Dpre, prescription dose, EUD equivalent
uniform dose, SFUD single field uniform dose, SFIB single-field integrated boost, IMPT intensity modulated proton therapy.
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experience suggests that not only does SFIB result in
superior treatment plans but also expedites treatment
planning and patient specific QA.
SSPT offers exciting and challenging new opportunities,
such as IMPT. In IMPT, the dose for each individual field
is highly inhomogeneous within each target volume.
When all fields are combined, the total doses would result
in the desired dose distribution for all target volumes.
Shown in Figure 6 are the IMPT plan dose distributions
from combined and individual fields for patient 4. There
is little difference between SFIB and IMPT for the
combined dose distributions (Figure 6A and B), except the
IMPT dose distribution is more conformal in certain areas
(arrow, Figure 6B). For both field one or two, the IMPT
plan shows much more inhomogenous dose distribution
than the SFIB plan. One could consider IMPT as a
sophisticated version of the patch/match technique,
sometimes used in passively scattered proton beam therapy
planning [1]. IMPT may produce more conformal dose
distributions, but may also be more sensitive to various
uncertainties, including setup and range uncertainties.
In the current work, worst case robust analysis showed
that IMPT were less robust than SFIB plans in terms of
target coverage. It should be pointed out that the
optimization phase space of a SFIB plan is a subset of
that of IMPT. In other words, it is possible, in theory, to
obtain a solution of SFIB with MFO. In practice, however,
one would never arrive at a solution of SFIB using
MFO due to very large number of degenerated solutions
available for MFO. In our clinical practice, we have also
found that the robustness of an IMPT plan is optimization
technique dependent; that is, IMPT plans generated by
some initial conditions are more robust than others. For
the examples presented here, the SFIB technique achievedthe similar dose conformity and normal tissue sparing to
IMPT and yet provided some assurance of robustness of
the plan.
The SFIB technique may not be ideally applied to all
cancer patients who received SSPT and require multiple
dose levels. For complex target volumes such as with
oropharyngeal and nasopharyngeal tumors requiring
treatment of the bilateral neck, it is recommended to
use IMPT as the planning method given the complex
geometry of the targets [19]. Indeed robust optimization,
considering various uncertainties, is recommended for
general IMPT planning [6,7,22].
The SFUD technique produces a flat depth dose
profile within the target along the beam direction by
the superposition of many spots with different energies.
However, a flat depth dose profile is not required with
SFO. In fact, the planner has all the degrees of freedom to
produce a non-uniform dose distribution along the beam
and lateral directions with SFO. SFO is a more general
concept than SFUD and may be used to generate either
SFUD or SFIB plans on a field-by-field basis. It should be
noted that identical beams were used for SFUD primary
and boost plans in this work. If different beam angles were
used for the boost SFUD plans, the normal tissues might
be better spared. However, this was not explored in the
current study.
In a planning study, Cozzia et al. proposed an SIB
technique based on SFUD for head and neck cancer
patients with two target volumes and two prescription
dose levels [23]. They optimized fields for each target
individually and then summed them to obtain the final
plan. In contrast to the SFUD-based SIB technique by
Cozzia et al. [23], the SFIB method presented in this



















Figure 6 Example of dose distributions of SFIB and IMPT for patient 4 in color wash to demonstrate the dose inhomogeneity of
individual fields of an IMPT plan. (A) SFIB and (B) IMPT for all fields; (C) SFIB and (D) IMPT for field one; and (E) SFIB and (F) IMPT for field two.
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http://www.ro-journal.com/content/9/1/202Compared with the SFUD sequential boost approach,
SFIB offers seamless delivery and more efficient treatment
planning and patient-specific QA (one plan for SFIB
vs. two or three plans for sequential boost SFUD).
We estimate that there is a 30% to 50% time saving
in both treatment planning and patient specific QA
with the SFIB technique. This increased efficiency
provides additional logistical and economic reasons for
treating patients with SFIB. Currently, proton therapy,
especially SSPT, is a limited resource available in theUnited States and around the world. As the SSPT
treatment process becomes more efficient, more patients
may benefit from this advanced form of radiation therapy.
The plans presented in this work used specific beam
settings available in our clinic, as detailed in Table 1. If
the beam settings were significantly different from these
in Table 1, some of the specific results might be different.
For example, if the spot size was much smaller, the spot
spacing should be smaller to keep the ratio spot spacing
to spot size in air ≤ 1.5. Then the conformal index would
Zhu et al. Radiation Oncology 2014, 9:202 Page 12 of 12
http://www.ro-journal.com/content/9/1/202be improved for all plans yet the robustness would be
reduced with respect to the setup uncertainties due to
sharper penumbra associated with smaller spot size.
However, one should expect that the SFIB still is a valid
planning technique to generate conformal and robust
plans for selected patients with relatively simple targets.
Conclusion
We have successfully implemented an SFIB technique based
on SFO for SSPT to treat a variety of cancer types. SFIB is a
natural application of SFO. When SFO is used, a uniform
dose across the target volume is not required. Therefore,
SFO is a general concept and can be used to generate either
SFUD or SFIB plans. SFIB often produces more conformal
plans compared to those with SFUD. Additional advantages
of SFIB are seamless delivery and more efficient treatment
planning and patient-specific QA. For relatively simple
target volumes presented in this work, we also demon-
strated that SFIB may be more robust than IMPT, yet has
similar conformity and normal tissue sparing.
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